81 related articles for article (PubMed ID: 476649)
1. Penetration of 3-deazauridine into human brain, intracerebral tumor, and cerebrospinal fluid.
Stewart DJ; Benvenuto JA; Leavens M; Hall SW; Benjamin RS; Plunkett W; McCredie KB; Burgess MA; Loo TL
Cancer Res; 1979 Oct; 39(10):4119-22. PubMed ID: 476649
[TBL] [Abstract][Full Text] [Related]
2. Penetration of methylglyoxal bis(guanylhydrazone) into intracerebral tumors in humans.
Rosenblum MG; Stewart DJ; Yap BS; Leavens M; Benjamin RS; Loo TL
Cancer Res; 1981 Feb; 41(2):459-62. PubMed ID: 7448791
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and disposition of 3-deazauridine in humans.
Benvenuto JA; Hall SW; Farquhar D; Stewart DJ; Benjamin RS; Loo TL
Cancer Res; 1979 Feb; 39(2 Pt 1):349-52. PubMed ID: 761206
[TBL] [Abstract][Full Text] [Related]
4. High-pressure liquid chromatographic analysis of 3-deazauridine-5'-triphosphate in human cancer cells.
Plunkett W; Benvenuto JA; Stewart DJ; Loo TL
Cancer Treat Rep; 1979 Mar; 63(3):415-20. PubMed ID: 284846
[TBL] [Abstract][Full Text] [Related]
5. Transport of uridine and 3-deazauridine in cultured human lymphoblastoid cells.
Dahlig-Harley E; Paterson AR; Robins MJ; Cass CE
Cancer Res; 1984 Jan; 44(1):161-5. PubMed ID: 6580947
[TBL] [Abstract][Full Text] [Related]
6. [Distribution of cis-diamminedichloroplatinum in patients with metastatic brain tumors after intravenous or intracarotid administration].
Nakagawa H; Fujita T; Izumoto S; Kubo S; Nakajima Y; Turuzono K
Gan To Kagaku Ryoho; 1991 Jan; 18(1):103-9. PubMed ID: 1987891
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic and biochemical effects of thymidine and 3-deazauridine on human tumor cells.
Lockshin A; Mendoza JT; Giovanella BC; Stehlin JS
Cancer Res; 1984 Jun; 44(6):2534-9. PubMed ID: 6722792
[TBL] [Abstract][Full Text] [Related]
8. 3-Deazauridine (NSC 126849): an interesting modulator of biochemical response.
Moriconi WJ; Slavik M; Taylor S
Invest New Drugs; 1986; 4(1):67-84. PubMed ID: 2422137
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma.
Zylber-Katz E; Gomori JM; Schwartz A; Lossos A; Bokstein F; Siegal T
Clin Pharmacol Ther; 2000 Jun; 67(6):631-41. PubMed ID: 10872645
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacokinetic analysis of ACNU in brain tumors (author's transl)].
Hara M; Takeuchi K
No To Shinkei; 1979 Dec; 31(12):1289-93. PubMed ID: 526372
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of tumor cell exposure to [14C]methotrexate after intracarotid administration without and with hyperosmotic opening of the blood-brain and blood-tumor barriers in rat brain tumors: a quantitative autoradiographic study.
Shapiro WR; Voorhies RM; Hiesiger EM; Sher PB; Basler GA; Lipschutz LE
Cancer Res; 1988 Feb; 48(3):694-701. PubMed ID: 3335031
[TBL] [Abstract][Full Text] [Related]
12. Cytidine and deoxycytidylate deaminase inhibition by uridine analogs.
Drake JC; Hande KR; Fuller RW; Chabner BA
Biochem Pharmacol; 1980 Mar; 29(5):807-11. PubMed ID: 20227960
[TBL] [Abstract][Full Text] [Related]
13. Concentration of vinblastine in human intracerebral tumor and other tissues.
Stewart DJ; Lu K; Benjamin RS; Leavens ME; Luna M; Yap HY; Loo TL
J Neurooncol; 1983; 1(2):139-44. PubMed ID: 6678966
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous determination of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and 3-deazauridine 5'-triphosphate in human leukemia cells by high-performance liquid chromatography.
Plunkett W; Chubb S; Barlogie B
J Chromatogr; 1980 Dec; 221(2):425-30. PubMed ID: 6938519
[No Abstract] [Full Text] [Related]
15. Plasma and cerebrospinal fluid pharmacokinetics of rebeccamycin (NSC 655649) in nonhuman primates.
Berg SL; Aleksic A; McGuffey L; Dauser R; Nuchtern J; Bernacky B; Blaney SM
Cancer Chemother Pharmacol; 2004 Aug; 54(2):127-30. PubMed ID: 15150671
[TBL] [Abstract][Full Text] [Related]
16. Enzyme pattern-directed chemotherapy: synergistic interaction of 3-deazauridine with D-galactosamine.
Jackson RC; Williams JC; Weber G
Cancer Treat Rep; 1976 Jul; 60(7):835-43. PubMed ID: 188552
[TBL] [Abstract][Full Text] [Related]
17. Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model.
Kaiser MG; Parsa AT; Fine RL; Hall JS; Chakrabarti I; Bruce JN
Neurosurgery; 2000 Dec; 47(6):1391-8; discussion 1398-9. PubMed ID: 11126910
[TBL] [Abstract][Full Text] [Related]
18. Altered 5-azacytidine metabolism following 3-deazauridine treatment of L5178Y and human myeloblasts.
Grant S; Cadman E
Cancer Res; 1980 Nov; 40(11):4000-6. PubMed ID: 6162541
[TBL] [Abstract][Full Text] [Related]
19. The disposition of 3-deazauridine in mice.
Cysyk RL; Gormley PE; D'Anna ME; Adamson RH
Drug Metab Dispos; 1978; 6(2):125-32. PubMed ID: 26526
[No Abstract] [Full Text] [Related]
20. Biodistribution of boron in dogs with spontaneous intracranial tumors following borocaptate sodium administration.
Kraft SL; Gavin PR; Leathers CW; DeHaan CE; Bauer WF; Miller DL; Dorn RV; Griebenow ML
Cancer Res; 1994 Mar; 54(5):1259-63. PubMed ID: 8118814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
